论文部分内容阅读
目的 探讨吡喃阿霉素 (THP)膀胱内灌注预防膀胱癌术后复发的疗效和安全性。方法 对 43例初发的浅表性膀胱癌术后患者定期进行THP膀胱内灌注治疗 ,随访 12～ 3 6个月。结果 无肿瘤复发率为 88.4% ,复发率为 11.6% ,12例于膀胱灌注期间出现膀胱刺激症状 ,其中 2例因为不能耐受 ,暂停灌注 ,其余患者均完成治疗。所有患者未见明显的全身性药物反应。结论 THP膀胱内灌注预防膀胱癌术后复发疗效满意 ,病人耐受性好 ,无全身性药物反应。
Objective To investigate the efficacy and safety of intravesical instillation of pirarubicin (THP) to prevent postoperative recurrence of bladder cancer. Methods Forty-three patients with superficial bladder cancer who underwent initial THP intravesical instillation were followed up for 12 to 36 months. Results No tumor recurrence rate was 88.4%, the recurrence rate was 11.6%, 12 cases of bladder irritation during bladder irrigation symptoms, of which 2 were unable to tolerate, the suspension of perfusion, and the remaining patients were completed treatment. No systemic systemic drug response was seen in all patients. Conclusion Intravesical instillation of THP is effective in preventing postoperative recurrence of bladder cancer. The patients are well tolerated and have no systemic drug reactions.